Blocknomi
Key Highlights Shares of Inhibrx Biosciences climbed 17% Monday following encouraging Phase 2 clinical trial data for INBRX-106 in head-and-neck cancer treatment. The experimental therapy paired with pembrolizumab delivered a…
Related articles
-
WHITE TECH joins Croatia’s first MiCA-approved crypto firms
Crypto.News Published 01.05.2026 12:52
-
Marscat And Origins Network Join Forces To Power Scalable Web3 Applications With Decentralized Cloud Computing
BlockchainReporter Published 01.05.2026 19:00
-
Moderna (MRNA) Stock Jumps 16% Following Positive Flu Vaccine Results and Wall Street Upgrades
Blocknomi Published 08.05.2026 16:51
-
Eric Trump at Consensus 2026: Why Big Finance’s Crypto Shift is Just the Beginning
Bitcoin.com Published 07.05.2026 19:05
-
Bitcoin briefly slips below $80,000, but options traders are betting the dip won’t last
CryptoSlate Published 09.05.2026 11:30
-
Alphabet (GOOGL) Stock Surges on Massive $200B Anthropic Cloud Partnership
Blocknomi Published 06.05.2026 13:05
-
Here’s why the crypto market is falling today
Crypto.News Published 30.04.2026 09:04
-
Tether-backed Oobit rolls out virtual Visa cards for AI agent USDT spending
Cointelegraph Published 01.05.2026 02:11